To assess whether modulating the transcription of cell-cycle or mitochondrial genes could affect patient survival, we examined a gene expression dataset previously published as part of the APEX trial (4, 28) where the global transcriptome was analyzed in CD138+ multiple myeloma cells of 264 patients with relapsed and refractory disease. The gene discussed is SDC1; the disease is plasma cell myeloma.